Alteogen, a bio platform company, announced through a disclosure on November 14 that it achieved consolidated cumulative sales of 151.4 billion won ...

Abstract: In this paper, we report a novel three-state Radio Frequency Microelectromechanical Systems (RF MEMS) switch, which is based on origami structure for large tunable capability. Combined with ...

Additional updates from the ongoing Phase 1b/2 trial with muzastotug, previously reported at ASCO 2025, are anticipated in the coming months SAN DIEGO and SUZHOU, China, Oct. 31, 2025 (GLOBE NEWSWIRE) ...

Merck shares have floundered this year, as the company speeds like a whistling locomotive toward the expiration of the patents protecting its megablockbuster cancer immunotherapy Keytruda.

Merck (NYSE:MRK) is set to report its third-quarter earnings on Thursday, October 30, before the market opens. Consensus estimates call for earnings per share of $2.35, up 49.7% year over year, and ...

Merck & Co. and Eisai previously had high hopes for their Keytruda-Lenvima combination in a liver cancer subtype based on positive progression-free survival data, but now the combo’s promise has once ...

As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a bit brighter in the glow of two late-stage trial wins for cancer drug Welireg ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. NNK Group Ltd ( (HK:3773)) has shared an ...

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its top-selling immunotherapy Keytruda loses patent protection. In kidney cancer, ...

Abstract: We proposed a new model for gated-anode diodes (GADs) based on gallium nitride (GaN) high-electron mobility transistors (HEMTs) to optimize the device structure toward efficient microwave ...